Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$57.02 USD

57.02
567,398

+0.73 (1.30%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $57.03 +0.01 (0.02%) 6:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Joint (JYNT) Expands Operations to Alaska With 3 Clinics

by Zacks Equity Research

The Joint's (JYNT) expansionary move is expected to be a prudent one, given the growing demand for affordable and convenient chiropractic care in the region.

Quest Diagnostics (DGX) Volume Growth Aids, Margin Woes Stay

by Zacks Equity Research

Quest Diagnostics' (DGX) legacy base business is growing amid softer utilization trends.

Centene (CNC) Concludes Magellan Rx Divestment to Prime

by Zacks Equity Research

Centene (CNC) completes Magellan Rx divestment within the scheduled time.

Here's Why You Should Retain Hologic (HOLX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on the back of its continued strength in the Breast Health arm.

Catalent (CTLT) Expands Facility Capabilities in Shanghai

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the clinical trials space in its Asia-Pacific Clinical Supply Services network.

Masimo (MASI) Announces Positive Study Results on PBM by SpHb

by Zacks Equity Research

Masimo's (MASI) SpHb is likely to enhance transfusion management and post-operative patient outcomes on patients.

Merit Medical (MMSI) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Merit Medical's (MMSI) slew of product launches.

Thermo Fisher (TMO) End Markets Grow Strong, Margin Woe Stays

by Zacks Equity Research

Thermo Fisher (TMO) witnesses strength in three of its four end markets, categorized either by customer type or geography.

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

AMN or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY23 View

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both of its segments.

Humana (HUM) Ups '23 Medicare Advantage Membership Growth View

by Zacks Equity Research

Humana (HUM) expects 2023 net membership gains to be a minimum of 10.9% from the 2022 projection.

Why You Should Retain Centene (CNC) in Your Portfolio Now

by Zacks Equity Research

Divesting operations like PANTHERx, Magellan Specialty Health and others are going to enable Centene (CNC) to intensify its focus on its core Managed Care business.

Acadia (ACHC) JV Opens New Behavioral Health Unit in Fort Wayne

by Zacks Equity Research

The opening of the new hospital is in line with Acadia Healthcare's (ACHC) vision to bolster its reach in the U.S. behavioral healthcare market.

Henry Schein's (HSIC) New Tie-Up to Improve Patient Outcome

by Zacks Equity Research

Henry Schein's (HSIC) recent deal with VideaHealth is expected to aid dentists in proving greater transparency to patients, thus making better treatment recommendations and improving case acceptance.

Molina Healthcare (MOH) Up 11% in 6 Months: More Room to Run?

by Zacks Equity Research

Molina Healthcare (MOH) is well-poised for growth on growing premiums, membership increases in Government business and sufficient cash reserves.

Boston Scientific's (BSX) New Buyout to Expand its Portfolio

by Zacks Equity Research

Boston Scientific's (BSX) latest buyout is expected to boost its Endoscopy business by adding Apollo Endosurgery's product portfolio, which includes devices used during ELS procedures.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.

3 Reasons Growth Investors Will Love AMN Healthcare (AMN)

by Zacks Equity Research

AMN Healthcare (AMN) possesses solid growth attributes, which could help it handily outperform the market.

Here's Why You Should Hold OPKO Health (OPK) Stock For Now

by Zacks Equity Research

OPKO Health (OPK) is likely to gain from the potential in RAYALDEE that targets a growing market coupled with new collaborations and acquisitions.

Merit Medical (MMSI) Launches New Inflation Device basixALPHA

by Zacks Equity Research

Merit Medical (MMSI) launches basixALPHA inflation device in the United States for one-handed preparation and fast inflation with minimal exertion to streamline angioplasty procedures.

What You Need to Know From UnitedHealth's (UNH) Latest Outlook

by Zacks Equity Research

UnitedHealth (UNH) expects the top line to be within the range of $357-$360 billion in 2023.

AmerisourceBergen (ABC) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

Boston Scientific (BSX) Posts Positive Post-Market Study Data

by Zacks Equity Research

The latest PMCF study demonstrates that Boston Scientific's (BSX) ACURATE neo2 Aortic Valve System is expected to significantly improve patient outcomes.